GlassScriptPhysician profile
Thomas Joseph Richard
NPI 1649255928
$2,007.22
in general payments reported to CMS, 2019-2025
29 companies · $707 in 2025
The $707 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.74 · 2020: $52.17 · 2021: $11.92 · 2022: $112 · 2023: $268 · 2024: $843 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,696.18 |
| Education | $121.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $250.60 | 2022-2025 | Opdualag, Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $186.02 | 2023-2025 | |
| Pfizer INC. | $145.84 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $135.38 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $112.37 | 2022-2024 | Tecentriq, Alecensa, Rozlytrek |
| Gilead Sciences, INC. | $108.63 | 2021-2025 | Trodelvy |
| Janssen Biotech, INC. | $99.99 | 2024 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $98.72 | 2020-2024 | Iclusig |
| Exelixis INC. | $84.66 | 2023-2025 | Cabometyx |
| Eisai INC. | $75.76 | 2022-2025 | |
| Daiichi Sankyo INC. | $74.02 | 2024-2025 | Enhertu |
| Servier Pharmaceuticals LLC | $58.72 | 2023-2024 | |
| Incyte Corporation | $51.85 | 2023-2024 | Monjuvi, Pemazyre |
| Array Biopharma INC | $51.83 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Seagen INC. | $50.44 | 2022-2023 | Adcetris, Padcev |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.73 | 2022-2023 | Lumakras |
| Aveo Pharmaceuticals, INC. | $41.01 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.53 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $36.57 | 2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $35.58 | 2024-2025 | |
| Abbvie INC. | $32.50 | 2025 | |
| Deciphera Pharmaceuticals INC. | $31.40 | 2024-2025 | Qinlock, Romvimza |
| Geron Corporation | $28.09 | 2025 | Rytelo |
| Sobi, INC | $25.32 | 2025 | |
| Stemline Therapeutics INC. | $25.12 | 2024 | Elzonris |
| Lilly USA, LLC | $24.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $18.82 | 2025 | Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $15.84 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Richard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.